Advanced MR Analytics (AMRA) has received an investment of approximately 8.5 million euros ($9 million U.S.) from U.S.-based Pfizer Venture Investments, Nordic VC Novo Seeds, and Industrifonden, another AMRA investor.
The plan is to use the funds to advance the company's MRI research into the relationship between fat, muscle, and the development of disease, and to redefine obesity and metabolic risk using a personalized medicine approach.
AMRA has a cloud-based, computer-aided service known as AMRA Profiler, which translates data from a six-minute whole-body MRI scan into fat and muscle measurements.
The AMRA Profiler has received the CE Mark for clinical use in Europe.
